Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LUCD Lucid Diagnostics	$1.17 -1.7%	$1.28	$0.72 ▼ $1.80	$128.74M	1.31	649,053 shs	9.84 million shs
OBIO Orchestra BioMed	$2.78 -6.7%	$2.92	$2.37 ▼ $8.87	$114.17M	0.64	189,625 shs	3.18 million shs
PEYE Precision Optics		$0.00	$1.61 ▼ $2.69	$32.98M	0.41	9,793 shs	113,500 shs
RCEL Avita Medical	$5.45 +6.4%	$6.97	$4.71 ▼ $14.16	$135.35M	1.55	186,881 shs	765,366 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LUCD Lucid Diagnostics	-1.68%	-7.14%	-23.03%	-25.95%	+39.15%
OBIO Orchestra BioMed	-6.71%	-7.64%	-5.76%	-36.82%	-59.48%
PEYE Precision Optics	0.00%	0.00%	0.00%	0.00%	0.00%
RCEL Avita Medical	+6.45%	+5.42%	-12.24%	-37.57%	-31.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LUCD Lucid Diagnostics	3.0439 of 5 stars	3.6	3.0	0.0	0.0	3.3	1.7	0.6
OBIO Orchestra BioMed	2.9121 of 5 stars	3.6	5.0	0.0	0.0	2.0	1.7	0.0
PEYE Precision Optics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCEL Avita Medical	1.2601 of 5 stars	3.4	0.0	0.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LUCD Lucid Diagnostics	3.20	Buy	$3.55	203.42% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.20	410.79% Upside
PEYE Precision Optics	0.00	N/A	N/A	N/A
RCEL Avita Medical	2.75	Moderate Buy	$16.50	202.75% Upside

Current Analyst Ratings Breakdown

Latest PEYE, RCEL, LUCD, and OBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
6/6/2025	RCEL Avita Medical	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/10/2025	RCEL Avita Medical	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LUCD Lucid Diagnostics	$4.35M	29.10	N/A	N/A	($0.78) per share	-1.50
OBIO Orchestra BioMed	$2.64M	40.34	N/A	N/A	$0.87 per share	3.20
PEYE Precision Optics	$15.68M	0.00	N/A	N/A	$0.53 per share	0.00
RCEL Avita Medical	$64.25M	2.24	N/A	N/A	$0.17 per share	32.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LUCD Lucid Diagnostics	-$45.53M	-$1.34	N/A	N/A	N/A	-1,699.86%	N/A	-124.27%	8/11/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A
PEYE Precision Optics	-$930K	-$0.06	N/A	N/A	N/A	-5.93%	-12.10%	-6.41%	N/A
RCEL Avita Medical	-$61.85M	-$2.19	N/A	N/A	N/A	-79.61%	-632.62%	-71.72%	8/6/2025 (Estimated)

Latest PEYE, RCEL, LUCD, and OBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million
5/8/2025	Q1 2025	RCEL Avita Medical	-$0.39	-$0.53	-$0.14	-$0.53	$33.15 million	$18.51 million
3/31/2025	Q4 2024	OBIO Orchestra BioMed	-$0.43	-$0.43	N/A	-$0.43	$0.79 million	$0.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A
PEYE Precision Optics	N/A	N/A	N/A	N/A	N/A
RCEL Avita Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LUCD Lucid Diagnostics	N/A	0.75	0.74
OBIO Orchestra BioMed	0.85	3.35	3.34
PEYE Precision Optics	0.23	1.42	0.76
RCEL Avita Medical	9.39	2.09	1.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LUCD Lucid Diagnostics	74.01%
OBIO Orchestra BioMed	53.55%
PEYE Precision Optics	N/A
RCEL Avita Medical	27.66%

Insider Ownership

Company	Insider Ownership
LUCD Lucid Diagnostics	6.80%
OBIO Orchestra BioMed	8.10%
PEYE Precision Optics	22.70%
RCEL Avita Medical	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LUCD Lucid Diagnostics	70	108.19 million	100.83 million	No Data
OBIO Orchestra BioMed	4	38.31 million	35.21 million	Not Optionable
PEYE Precision Optics	80	16.92 million	13.08 million	Not Optionable
RCEL Avita Medical	130	26.43 million	25.70 million	Optionable

PEYE, RCEL, LUCD, and OBIO Headlines

Recent News About These Companies

AVITA Medical, Inc. (RCEL) - Yahoo Finance

June 27 at 8:05 PM | finance.yahoo.com

Analysts Expect Breakeven For AVITA Medical, Inc. (NASDAQ:RCEL) Before Long

June 21, 2025 | finance.yahoo.com

Cantor Fitzgerald Predicts AVITA Medical FY2026 Earnings

June 11, 2025 | marketbeat.com

AVITA Medical (NASDAQ:RCEL) Given Buy Rating at D. Boral Capital

June 6, 2025 | marketbeat.com

AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

June 5, 2025 | finance.yahoo.com

AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards

June 3, 2025 | globenewswire.com

Short Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Rises By 23.9%

June 3, 2025 | marketbeat.com

AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today

May 13, 2025 | finance.yahoo.com

AVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet Challenges

May 12, 2025 | seekingalpha.com

Analysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest Report

May 11, 2025 | finance.yahoo.com

AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

AVITA Medical Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

AVITA Medical to Announce First Quarter 2025 Financial Results

April 17, 2025 | globenewswire.com

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

April 9, 2025 | globenewswire.com

6 Analysts Assess AVITA Medical: What You Need To Know

April 6, 2025 | nasdaq.com

Avita Medical announces U.S. commercial launch of Cohealyx

April 4, 2025 | msn.com

AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

April 3, 2025 | globenewswire.com

AVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdles

March 21, 2025 | uk.investing.com

4RCEL : What Analysts Are Saying About AVITA Medical Stock

March 18, 2025 | benzinga.com

Avita Medical amends PermeaDerm distribution agreement with Stedical Scientific

March 17, 2025 | markets.businessinsider.com

Avita Medical Boosts Production with New Agreement

March 17, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
UPS Is Outpacing the Market: A Green Light for Investors?
By Jeffrey Neal Johnson | June 27, 2025
View UPS Is Outpacing the Market: A Green Light for Investors?

PEYE, RCEL, LUCD, and OBIO Company Descriptions

Lucid Diagnostics NASDAQ:LUCD

$1.17 -0.02 (-1.68%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.15 -0.02 (-1.71%)

As of 06/27/2025 07:59 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Orchestra BioMed NASDAQ:OBIO

$2.78 -0.20 (-6.71%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.79 +0.01 (+0.36%)

As of 06/27/2025 07:10 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Precision Optics OTCMKTS:PEYE

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.

Avita Medical NASDAQ:RCEL

$5.45 +0.33 (+6.45%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.30 -0.15 (-2.75%)

As of 06/27/2025 07:57 PM Eastern

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time